Search peptides, terms, sources/
Brain and mood

Semax

Also known as: ACTH heptapeptide analog

Synthetic ACTH-derived peptide studied for brain function and stroke recovery. Not licensed in the UK; evidence is mainly rodent studies.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

3 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Semax is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials1 human trial · 2 animal studies

What is Semax?

Semax is a synthetic heptapeptide analogue of a fragment of the hormone ACTH, studied for brain function and recovery after stroke. It is not licensed in the UK, and the evidence is mainly rodent studies plus a small number of human reports from a single research programme.

It is based on ACTH(4-10) and was designed without ACTH's hormonal (corticotropic) activity. The human research includes a trial in patients with acute ischaemic stroke.

Class
ACTH-derived nootropic/neuroprotective peptide
Origin
Fragment / derived
Research areas
Cognitive Research
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Semax work?

Semax is a shortened ACTH fragment without ACTH's effect on the adrenal glands. In rodents it activates dopamine and serotonin systems and raises BDNF, a protein that supports nerve cells. In a human stroke report, blood BDNF rose, but that trial could not show a causal link.

The mechanism in more detail

Semax has been reported, across a series of Russian-led pharmacology studies, to activate dopaminergic and serotonergic neurotransmitter systems in rodents, while lacking the corticotropic, or adrenal-stimulating, activity of native ACTH(4-10). Separately, animal studies have shown Semax to up-regulate brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the rat hippocampus, an effect proposed as central to its reported cognitive and neuroprotective activity.

In a human trial of patients with acute hemispheric ischaemic stroke, intranasal Semax administration was associated with increased plasma BDNF alongside improvements in motor performance and functional-independence scores. The trial’s own authors proposed a mechanistic link between the BDNF change and the clinical improvement, but this link was not established as causal within that single trial’s design. As with the animal pharmacology data, this finding comes from a single research programme, and the published report of the 110-patient trial does not state whether patients were randomised or blinded.

Mechanisms and targets

Dopaminergic/serotonergic modulationNeuroprotection (proposed)Neurotrophic-factor upregulation (BDNF/NGF)BDNF/TrkB signallingDopaminergic neurotransmitter systemSerotonergic neurotransmitter system

Classification and structure

Names
Semax; ACTH(4-10) heptapeptide analog
Class
ACTH-derived nootropic/neuroprotective peptide
Origin
Fragment / derived
Structure
Met-Glu-His-Phe-Pro-Gly-Pro. Retains the native ACTH(4-7) sequence (Met-Glu-His-Phe) but replaces the native ACTH(8-10) tripeptide (Arg-Trp-Gly) with a synthetic Pro-Gly-Pro tail, conferring resistance to plasma peptidase degradation and removing corticotropic (adrenal-stimulating) activity. Molecular formula C37H51N9O10S, MW 813.93 Da. Developed at the Institute of Molecular Genetics, Russian Academy of Sciences.
Routes used in the research
Intranasal administration in both the animal pharmacology literature and the human stroke trial reviewed. This is a research-methodology detail, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Semax has 3 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

3 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
03000

Acute ischaemic stroke trial Limited

In a 2018 report of 110 post-stroke patients in early and late rehabilitation, intranasal Semax was associated with increased plasma BDNF, improved motor performance, and improved functional-independence scores (Barthel Index) relative to comparison.

Study type
Human trial
Population
110 post-stroke patients (43 men, 67 women) in early and late rehabilitation groups
Source
1 Gusev et al., 2018

Limitation: The 2018 report does not state whether patients were randomised or blinded.

Limitations in full

The 2018 report does not state whether patients were randomised or blinded. An earlier study from the same research programme compared 30 Semax-treated patients with 80 patients on conventional therapy; randomisation is not stated there either. Single research programme.

Rodent neurotransmission activity Limited

Semax activates dopaminergic and serotonergic neurotransmission in rodents and does not exhibit the corticotropic (adrenal-stimulating) hormonal activity of native ACTH(4-10).

Study type
Animal
Population
Rodents
Source
2 Eremin et al., 2005

Limitation: Single study or research programme in the sources reviewed.

Rat hippocampal BDNF expression Limited

Semax up-regulates BDNF and TrkB receptor expression in the rat hippocampus.

Study type
Animal
Population
Rats
Source
3 Dolotov et al., 2006

Limitation: Single study; mechanistic; no replication outside the originating research programme has been identified.

What safety findings have been reported?

1 safety finding is recorded for Semax. A short list does not mean a substance is safe; it reflects what has been studied and reported.

No human adverse-event dataset

No systematic, independently verified human adverse-event dataset has been identified.

Source
1 Gusev et al., 2018

What is Semax's UK regulatory status?

Marketing authorisation
None. No MHRA marketing authorisation exists for Semax in the UK. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for Semax.
Prescription status
Not applicable; no licensed UK product exists to classify.
Medicine class
Would meet the Human Medicines Regulations 2012 (SI 2012/1916), Regulation 2 definition of a "medicinal product" if administered or marketed with a view to a pharmacological or physiological effect, an unlicensed medicinal product in the UK on that basis.
MHRA position
Unlicensed medicinal product if supplied or marketed for human administration with a therapeutic or cognitive-enhancement purpose in the UK.
Authorised use
None in the UK.
Other restrictions
None identified beyond the standard unlicensed-medicine enforcement framework in the UK. A 2022 review (Deigin et al., Pharmaceutics) lists Semax among peptide drugs registered in Russia as a nootropic and says it is used for ischaemic stroke.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Semax is recorded as not licensed in the UK (checked 14 November 2026).

References

4 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 118(3 Pt 2):61-68 (in Russian)Human clinical trial · DOI 10.17116/jnevro20181183261-68 · PMID 29798983 · Original ↗
  2. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12):1493-1500Animal-preclinical · DOI 10.1007/s11064-005-8826-8 · PMID 16362768 · Original ↗
  3. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1):54-60Animal-preclinical · DOI 10.1016/j.brainres.2006.07.108 · PMID 16996037 · Original ↗
  4. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Semax

What is Semax?

Semax is a synthetic heptapeptide analogue of a fragment of the hormone ACTH, studied for brain function and recovery after stroke. It is not licensed in the UK, and the evidence is mainly rodent studies plus a small number of human reports from a single research programme. Read what it is.

Is Semax licensed in the UK?

PeptGuru records Semax's UK status as: Not licensed in the UK. None. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Semax show?

PeptGuru records 3 research findings for Semax: 1 from a human trial and 2 from animal studies. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Semax?

1 safety finding is recorded, including: no human adverse-event dataset. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Semax?

All 4 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · The 110-patient stroke finding is now cited to the correct study (Gusev et al., 2018). It was previously linked to a different 1997 study.
  • Regulatory update · UK status now cites a dated MHRA database check.

How findings are graded: the grading method. All changes.

  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK
  • Oxytocin

    Natural hormone licensed in the UK for obstetric use; studied separately for social cognition, with mostly negative trial results.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedLicensed for a different use
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • SelankTP-7

    Synthetic tuftsin-derived peptide studied for anxiety. Not licensed in the UK; main human evidence is one active-comparator trial.

    Brain and moodHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare Semax with KPV

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.